**Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against**

**JN.1 Subvariants in Adult Participants**

**Authors**: Amparo L. Figueroa,[1] Bethany Girard,[1] Darin K Edwards,[1] Arshan Nasir,[1]
Kimball Johnson,[2] Steven Hack,[1] Xin Cao,[1] Elizabeth de Windt,[1] Veronica Urdaneta,[1]
Frances Priddy,[1] Rituparna Das,[1] David C Montefiori,[3] Spyros Chalkias[1]

**Affiliations**: [1]Moderna, Inc., Cambridge, Massachusetts 02142, USA; [2]CenExel,
Decatur, Georgia 30030, USA; [3]Duke University Medical Center, Durham, North
Carolina 27710, USA.

**Running title:** Evaluation of JN.1 and KP.2 Vaccines

**Corresponding author**:

Amparo L. Figueroa

Moderna, Inc., 325 Binney Street, Cambridge, MA, USA 02142

Phone: 1-617-335-3762

amparo.figueroa@modernatx.com

**Abstract**

COVID-19 vaccines encoding JN.1 (mRNA-1273.167) and KP.2 (mRNA-1273.712)

were approved for the immunization programs for the 2024-2025 season. This

ongoing, open-label, phase 3b/4 study evaluated the safety and immunogenicity of

mRNA-1273.167 and mRNA-1273.712 against vaccine-matched variants and JN.1-

lineage subvariants (KP.3.1.1, XEC, LP.8.1) in adults with previous COVID-19 mRNA

vaccination. Each of the two groups independently enrolled 50 participants. Both

JN.1 and KP.2 vaccines increased neutralizing antibody responses at Day 29 against

vaccine-matched variants, as well as against KP.3.1.1, XEC, and LP.8.1. Reduction

in cross-neutralization was observed across all tested subvariants compared with the

reference variant JN.1.No safety concerns were identified.

**Keywords**: immunogenicity, SARS-CoV-2, KP.2 vaccine, JN.1 vaccine, mRNA-1273

**Background**

The rapid spread and diversification of the SARS-CoV-2 Omicron lineage has given rise to the JN.1 variant, which became globally dominant by early 2024 [1] due to enhanced immune-evasion capabilities conferred by a receptor-binding domain (RBD) mutation, L455S, over its parental lineage BA.2.86 [2]. The JN.1 lineage continues to diversify through stepwise evolution or recombination, with KP.2 having circulated previously, and KP.3.1.1, XEC, and LP.8.1 currently in circulation worldwide [3]. XEC, a lineage derived via recombination of the two JN.1 subvariants, has a global presence [4, 5] and is characterized by 2 new mutations in the N-terminal domain (NTD) of the spike, T22N and F59S, compared with the previously dominant KP.3 [4, 6]. More recently, XEC is increasingly outcompeted by LP.8.1, a subvariant of KP.1.1.3 that contains 9 new spike mutations beyond those present in JN.1 [5, 6] and 6 new spike mutations compared with KP.2 [3]. LP.8.1 has already become dominant in the United States and is increasing in prevalence globally [5, 7]. While LP.8.1 seems to be no more immune-evasive than XEC, it shows enhanced spike-hACE2 engagement, which likely contributes to its increased fitness and gradual variant replacement over XEC [6]. Due to increasing global prevalence, XEC and LP.8.1 have been classified as variants under monitoring by the World Health Organization [3] and account for 76% of sequenced variants (LP.8.1: 55%; XEC: 21%) in the United States as of March 2025 [7].

The antigenic evolution within the SARS-CoV-2 JN.1 lineage led to authorization of monovalent variant formulations of mRNA COVID-19 vaccines (2024-2025 formula), which were updated to encode the JN.1 or KP.2 variant [8, 9]. Preclinical versions of the JN.1- and KP.2-encoding mRNA-1273 vaccines, administered both as a 2-dose primary series in naive mice and as a third (booster)

dose in previously immunized mice, were shown to drive neutralization against

vaccine-matched variants and to cross-neutralize JN.1 subvariants KP.2, KP.3, and

LA.2, as well as XEC evaluated in naïve mice only [10], thus supporting variant

selection and updated vaccine approvals. While the JN.1- and KP.2-encoding

mRNA-1273 vaccines are expected to remain cross-reactive to newly emerging

variants within the JN.1 lineage [5, 10], there are no clinical data available regarding

their cross-neutralizing potential.

This study was conducted as part of an ongoing phase 3b/4 trial

(NCT06585241) which aims to generate human serology data for the assessment of

immunogenicity and cross-neutralization of updated variant mRNA-1273 vaccines as

new SARS-CoV-2 variants emerge. Here, we evaluated the immunogenicity and

cross-neutralization of updated monovalent variant formulations of mRNA-1273

vaccines, the JN.1 vaccine (mRNA-1273.167) and the KP.2 vaccine (mRNA-

1273.712) against vaccine-matched variants and currently circulating and dominant

variants (KP.3.1.1, XEC, LP.8.1) [3, 7] in adults with previous COVID-19 mRNA

vaccination; safety was also evaluated.

**Methods**

*Study Design and Participants*

This is an ongoing, open-label, single-arm, phase 3b/4 study evaluating the

immunogenicity and safety of monovalent formulations of the mRNA-1273 vaccine

encoding the SARS-CoV-2 Omicron variants JN.1 (mRNA-1273.167) and KP.2

(mRNA-1273.712). Eligible participants were adults (aged ≥18 years) in the US who

had ≥3 previous mRNA COVID-19 vaccinations (≥2 mRNA COVID-19 vaccines and

an XBB.1.5-encoding mRNA COVID-19 vaccine received between September 2023

and August 2024). Participants received a 0.5-mL dose of a single intramuscular

injection (50 μg) of either mRNA-1273.167 (Subprotocol 1) or mRNA-1273.712

(Subprotocol 2) and were followed for 1 month after immunization. Adults with a

known history of SARS-CoV-2 infection within 3 months before enrollment were

excluded (**Supplementary Appendix**). The study is being conducted in accordance

with the Declaration of Helsinki and Council for International Organizations of

Medical Sciences international ethical guidelines, applicable International Council for

Harmonisation good clinical practice guidelines, and applicable laws and regulations.

The protocol, informed consent form, and other relevant documents were reviewed

and approved by the institutional review board/independent ethics committee before

study initiation. Informed consent was obtained prior to each participant's enrollment

into the study.

*Study Vaccines*

The mRNA-1273.167 vaccine (Spikevax, Moderna, Inc.) contains 50 μg of

mRNA encoding the full-length SARS-CoV-2 spike protein of the JN.1 variant with 2

proline residue substitutions to stabilize the spike protein into a prefusion

conformation. The mRNA-1273.712 vaccine contains 50 μg of mRNA encoding the

prefusion-stabilized spike protein of the KP.2 variant.

*Immunogenicity and Safety Assessments*

Sera for assessments of neutralizing antibody (nAb) responses were collected

before the variant vaccine was administered (Day 1) and 4 weeks after immunization

(Day 29). The nAb titers against vaccine-matched variants (JN.1, KP.2) and JN.1

subvariants (KP.3.1.1, XEC, LP.8.1) were quantified using a lentivirus-based SARS-

CoV-2 pseudovirus neutralization assay (Duke University), described previously [11].

Safety assessments included adverse events (AEs) leading to study withdrawal,

serious adverse events (SAEs), and AEs of special interest (AESIs) from Day 1

through the end of the study.

*Statistical Analysis*

Immunogenicity was evaluated in the per-protocol immunogenicity set (PPIS)

which comprised all participants who received a planned study vaccine, had a

negative reverse transcriptase polymerase chain reaction (RT-PCR) test at Days 1

and 29, and no major protocol deviations that impacted the key data. The geometric

mean (GM) titer and GM fold rise (GMFR) of nAb at Day 29 relative to baseline, with

corresponding 95% confidence intervals, were evaluated as a primary endpoint.

Safety was assessed in the safety set (all enrolled participants who received study

intervention). No statistical hypothesis testing was performed; a descriptive summary

of the primary immunogenicity objective was provided.

**Results**

Overall, 50 participants were independently enrolled in each subprotocol and

received mRNA-1273.167 (Subprotocol 1; median age, 63 years; 62% female; 86%

Black/African American) or mRNA-1273.712 (Subprotocol 2; median age, 54 years;

66% female; 70% Black/African American). The median time on study was 30 days

for the mRNA-1273.167 cohort and 29 days for the mRNA-1273.712 cohort. Prior

COVID-19 vaccines were categorized into 2, 3, 4, and ≥5 doses, with most

participants having received 3 doses (Subprotocol 1: 80%; Subprotocol 2: 76%); the

median time (interquartile range [IQR]) since last dose was 310 days (303-316) for

the mRNA-1273.167 cohort and 330 days (277-338) for the mRNA-1273.712 cohort.

Prior COVID-19 vaccination included an original mRNA monovalent formulation

(mRNA-1273 or BNT162b2; mRNA-1273.167, 100% recipients; mRNA-1273.712,

96% recipients), and Omicron bivalent formulation (mRNA-1273 or BNT162b2, 100%

recipients). Baseline SARS-CoV-2 status was determined by virologic (RT-PCR)

and/or serologic (anti-nucleocapsid binding antibody) evidence of SARS-CoV-2

infection on or before Day 1. No participants reported a known SARS-CoV-2

infection within the past 3 months. In Subprotocol 1, 39 (78.0%) participants were

SARS-CoV-2 positive at baseline; the PPIS included 48 (96.0%) participants (two

were excluded due to a missing or positive SARS CoV-2 RT-PCR result on Day 29).

In Subprotocol 2, 43 (86.0%) participants were SARS-CoV-2 positive at baseline; the

PPIS included 49 (98.0%) participants (one was excluded due to a positive or

missing SARS CoV-2 RT-PCR result on Day 29).

Both vaccines elicited robust increases in nAb responses at Day 29 relative to

baseline against matched variants (GMFR, 11.6-11.7) and cross-neutralized all

tested JN.1-lineage subvariants not matched to the vaccine (GMFR, mRNA-

1273.167: KP.2, 8.1; KP.3.1.1, 10.5; XEC, 12.9; LP.8.1, 10.8; GMFR, mRNA-

1273.712: JN.1, 10.8; KP.3.1.1, 12.4; XEC, 12.1; LP.8.1, 14.3; **Figure 1**). The highest

titers were measured against JN.1 for both vaccines (GMT: mRNA-1273.167,

1670.0; mRNA-1273.712, 2796.4). A reduction in cross-neutralization against

recently emergent subvariants of JN.1 (KP.3.1.1, XEC, and LP.8.1) relative to nAb

titers measured against the JN.1 reference variant was observed for both JN.1- and

KP.2-encoding vaccines, with the greatest reduction measured against KP.3.1.1

(**Figure 2**). The KP.2-encoding vaccine (mRNA-1273.712) drove higher nAb

responses than the JN.1-encoding vaccine (mRNA-1273.617) against all tested

variants (**Figure 2**).

No vaccine-related SAEs, AEs leading to study withdrawal, or AESIs were

reported following vaccination with mRNA-1273.167 or mRNA-1273.712 through the

end of study.

**Discussion**

In this phase 3b/4 study in previously COVID-19 vaccinated adults, the updated monovalent variant mRNA-1273 vaccines encoding the JN.1 (mRNA-1273.167) and KP.2 (mRNA-1273.712) variants induced robust nAb responses against the matched variants and cross-neutralized newly emerged JN.1 subvariants (KP.3.1.1, XEC, and LP.8.1), with a reduction in cross-neutralization observed across all subvariants tested compared with JN.1. No safety concerns were identified over the 1-month follow-up period. While both vaccines induced cross-neutralization in line with the expectation of potent cross-reactivity of the recommended JN.1- and KP.2-encoding vaccines against emerging JN.1-lineage subvariants [5, 10] decreased cross-neutralizing titers were measured against KP.3.1.1, XEC, and LP.8.1 for both vaccines; this suggests that more recently emerged variants have developed some immune escape from responses induced by currently approved COVID-19 vaccine compositions. At Day 29, the KP.2 vaccine (mRNA-1273.712) induced higher nAb responses than the JN.1 vaccine (mRNA-1273.167) against all variants tested, suggesting an advantage in preventing escape. The highest degree of reduction in cross-neutralization was observed for KP.3.1.1, in keeping with recent data reporting increased resistance to serum neutralization of KP.3.1.1 relative to XEC in KP.2-encoding vaccine recipients [12]. While the drop in cross-neutralization after the JN.1-encoding and KP.2-encoding vaccines against the JN.1 reference variant in this study ranged between 1.5 and 3.4 for all tested variants, it was lower than that previously reported against JN.1 (~5.8-fold reduction) after booster vaccination with the previously authorized (2023-2024 season) XBB.1.5-encoding mRNA-1273 monovalent vaccine [11]. Together, these data are consistent with recent reports of cross-neutralization induced by KP.2 monovalent boosters against

JN.1 subvariants, including KP.3.1.1 and XEC, along with observations of reduced

neutralization against these subvariants relative to JN.1 or KP.2 [13, 14]. Similar

neutralization performance was reported for the JN.1-encoding mRNA booster

vaccine among healthcare workers; the highest neutralization was measured against

JN.1, with 1.9- and 2.9-fold lower titers measured against KP.3.1.1 and XEC,

respectively [15].

The limitations of this study include a small sample size and the lack of

durability assessments of nAb responses over multiple time points. In addition,

higher baseline titers in the KP.2 vaccine arm might have contributed to the higher

nAb titers and fold-rises observed at Day 29, although fold-rises for KP.2, KP.3.1.1,

and LP.8.1 were greater in the KP.2 subprotocol despite higher baseline titers.

Notably, participant enrollment in the JN.1 and KP.2 vaccine arms was not

randomized, and, therefore, comparisons should be made with caution.

In conclusion, the JN.1- and KP.2-encoding monovalent mRNA-1273 vaccines

elicited robust neutralizing antibody responses against matched variants and cross-

neutralized currently circulating JN.1 subvariants KP.3.1.1, XEC, and LP.8.1, with a

reduction in cross-neutralization observed against all subvariants tested. No safety

concerns were identified.

**Footnotes**

These data were previously presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global), April 11-15, 2025, Vienna, Austria.

**Acknowledgments.** Medical writing and editorial assistance were provided by Anja Varjačić, PhD, of MEDiSTRAVA in accordance with Good Publication Practice (GPP 2022) guidelines, funded by Moderna, Inc., and under the direction of the authors.

**Author contributions.** A.L.F., B.G., D.K.E., A.N., S.H., X.C., E.d.W., V.U., F.P., R.D., and S.C. conceived and planned the study. A.L.F., B.G., A.N., K.J., S.H., E.d.W., V.U., R.D., and D.C.M. collected the data. A.L.F., B.G., D.K.E., A.N., S.H., X.C., E.d.W., V.U., R.D., D.C.M., and S.C. contributed to data analysis and interpretation. All authors contributed to drafting of the manuscript and contributed to the critical revision of the manuscript for important intellectual content. All authors met the authorship criteria and approved the publication.

**Financial support.** The study was supported by Moderna, Inc.

**Potential conflicts of interest.** A.L. F., B.G., D.K.E., A.N., S.H., X.C., E.D.W., V.U., F.P., R.D., and S.C., are employees of Moderna, Inc., and may hold stock/stock options in the company. K.J. is an employee of CenExel and holds stock in the company. D.C.M. reports laboratory funding from Moderna, Inc.

**Data availability statement**. As the trial is ongoing, access to patient-level data presented in the article and supporting clinical documents by qualified external researchers who provide methodologically sound scientific proposals may be available upon reasonable request for products or indications that have been approved by regulators in the relevant markets and subject to review from 24 months

225     after study completion. Such requests can be made to Moderna, Inc., 325 Binney

226     Street, Cambridge, MA, 02142 USA << data_sharing@modernatx.com>>. A

227     materials transfer and/or data access agreement with the sponsor will be required for

228     accessing shared data. All other relevant data are presented in the paper.

## References

1. World Health Organization. Updated Risk Evaluation of JN.1 09 February 2024. Available at: https://cdn.who.int/media/docs/default-source/documents/health-topics/sars/jn.1-9-february-2024.pdf. Accessed December 12 2024.

2. Li L, Shi K, Gu Y, et al. Spike structures, receptor binding, and immune escape of recently circulating SARS-CoV-2 Omicron BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 sub-variants. Structure **2024**; 32:1055-67.e6.

3. World Health Organization. WHO COVID-19 dashboard. Available at: https://data.who.int/dashboards/covid19/variants. Accessed March 4 2025.

4. Kaku Y, Okumura K, Kawakubo S, et al. Virological characteristics of the SARS-CoV-2 XEC variant. Lancet Infect Dis **2024**; 24:e736.

5. World Health Organization. Initial Risk Evaluation of LP.8.1 03 February 2025. Available at: https://www.who.int/publications/m/item/risk-evaluation-for-sars-cov-2-variant-under-monitoring-lp81. Accessed March 4 2025.

6. Liu J, Yu Y, Yang S, et al. Virological and antigenic characteristics of SARS-CoV-2 variants LF.7.2.1, NP.1, and LP.8.1. Lancet Infect Dis **2025**; 25:e128-30.

7. Centers for Disease Control and Prevention. COVID Data Tracker. Available at: https://covid.cdc.gov/covid-data-tracker/#variant-summary. Accessed April 11 2025.

8. World Health Organization. Statement on the Antigen Composition of COVID-19 Vaccines. Available at: https://www.who.int/news/item/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines. Accessed March 4 2025.

9. Food and Drug Administration. FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently. Accessed March 4 2025.

10. Lee DW, Nasir A, Elbashir S, et al. mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice. Vaccine **2025**; 54:126961.

11. Chalkias S, McGhee N, Whatley JL, et al. Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines. J Infect Dis **2024**; 230:e279-86.

12. Wang Q, Guo Y, Mellis IA, et al. Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC. bioRxiv **2024**:2024.11.17.624037.

13. Suthar MS, Manning KE, Ellis ML, et al. The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant. Lancet Infect Dis **2025**; 25:e122-3.

14. Wang Q, Mellis IA, Wu M, et al. KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2. Lancet Infect Dis **2025**; 25:e133-4.

15. Arora P, Happle C, Kempf A, et al. Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC. Lancet Infect Dis **2024**; 24:e732-3.

**Figure Legends**

**Figure 1**. Neutralizing antibody responses (GMT and GMFR) elicited by mRNA-1273.167 (JN.1-encoding vaccine) and mRNA-1273.712 (KP.2-encoding vaccine) against the vaccine-matched variants (JN.1, KP.2) and newly emerged subvariants (KP.3.1.1, XEC, LP.8.1), per-protocol immunogenicity set.

The GMT (Day 1 and Day 29) with the corresponding GMFR (Day 29 relative to Day 1) are shown. The per-protocol immunogenicity set included participants who received the planned study intervention, had negative RT-PCR tests at baseline (Day 1) and Day 29, and had no major protocol deviations that impacted the key data. The boundary of boxes represents the 25th (bottom) and 75th (top) percentiles of the GMT. The solid line inside the box represents the median (50th percentile) of the GMT. The dashed line inside the box represents the GMT. Whiskers (vertical lines) represent the lowest and highest data points within 1.5 of the interquartile range. The LLOQ is presented using a grey dashed line. The LOD is presented using a brown dashed line.

Abbreviations: GMFR, geometric mean fold rise; GMT, geometric mean titer; $ID_{50}$, 50% inhibitory dilution; LLOQ, lower limit of quantification; LOD, limit of detection; RT-PCR, reverse transcription polymerase chain reaction.

**Figure 2**. Geometric mean fold-drop in variant-specific neutralizing antibody

responses at Day 29 after mRNA-1273.167 (JN.1-encoding vaccine) and mRNA-

1273.712 (KP.2-encoding vaccine), per-protocol immunogenicity set.

The LLOQ is presented using a grey dashed line. The LOD is presented using a

brown dashed line.

Annotated fold change indicates fold-drop compared with the reference variant JN.1.

Abbreviations: LLOQ, lower limit of quantification; LOD, limit of detection.

**Figure Alt Text**

**Figure 1**: Graphs showing neutralizing antibody responses against vaccine-matched variants and newly emerged variants at baseline and Day 29 after JN.1- and KP.2-encoding mRNA-1273.712 vaccines, illustrated with boxplots and individual data points.

**Figure 2**: Graphs comparing geometric mean fold-drop in variant-specific neutralizing antibody responses at Day 29 after JN.1- and KP.2-encoding mRNA-1273.712 vaccines, illustrated with bars and individual data points.

**Figure 1**. Neutralizing antibody responses elicited by mRNA-1273.167 (JN.1 vaccine) and mRNA-1273.712 (KP.2 vaccine) against the vaccine-matched variants (JN.1, KP.2) and newly emerged variants (KP.3.1.1, XEC, LP.8.1), per-protocol immunogenicity set.

**Figure 2**. Geometric mean fold-drop in variant-specific neutralizing antibody responses at Day 29 after mRNA-1273.167 (JN.1 vaccine) and mRNA-1273.712 (KP.2 vaccine), per-protocol immunogenicity set.